Llwytho...
Targeted therapies for myeloproliferative neoplasms
The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. The JAK 1/2 inhibitor ruxolitinib was a pivotal moment...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Biomark Res |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6636147/ https://ncbi.nlm.nih.gov/pubmed/31346467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-019-0166-y |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|